Croatia - Croat - HALMED (Agencija za lijekove i medicinske proizvode)

alvogen malta operations (row) ltd., malta life sciences park, building 1, level 4, sir temi zammit buildings, san gwann, malta - temozolomidum - kapsula, tvrda - 100 mg - urbroj: jedna tvrda kapsula sadrži 100 mg temozolomida

Croatia - Croat - HALMED (Agencija za lijekove i medicinske proizvode)

alvogen malta operations (row) ltd., malta life sciences park, building 1, level 4, sir temi zammit buildings, san gwann, malta - temozolomidum - kapsula, tvrda - 140 mg - urbroj: jedna tvrda kapsula sadrži 140 mg temozolomida

Croatia - Croat - HALMED (Agencija za lijekove i medicinske proizvode)

alvogen malta operations (row) ltd., malta life sciences park, building 1, level 4, sir temi zammit buildings, san gwann, malta - temozolomidum - kapsula, tvrda - 180 mg - urbroj: jedna tvrda kapsula sadrži 180 mg temozolomida

Croatia - Croat - HALMED (Agencija za lijekove i medicinske proizvode)

alvogen malta operations (row) ltd., malta life sciences park, building 1, level 4, sir temi zammit buildings, san gwann, malta - temozolomidum - kapsula, tvrda - 20 mg - urbroj: jedna tvrda kapsula sadrži 20 mg temozolomida

Croatia - Croat - HALMED (Agencija za lijekove i medicinske proizvode)

alvogen malta operations (row) ltd., malta life sciences park, building 1, level 4, sir temi zammit buildings, san gwann, malta - temozolomidum - kapsula, tvrda - 250 mg - urbroj: jedna tvrda kapsula sadrži 250 mg temozolomida

Croatia - Croat - HALMED (Agencija za lijekove i medicinske proizvode)

alvogen malta operations (row) ltd., malta life sciences park, building 1, level 4, sir temi zammit buildings, san gwann, malta - temozolomidum - kapsula, tvrda - 5 mg - urbroj: jedna tvrda kapsula sadrži 5 mg temozolomida

Bosnia dan Herzegovina - Croat - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

takeda pharmaceuticals bh d.o.o. sarajevo - velagluceraze alfa - prašak za otopinu za infuziju - 400 jedinica/1 bočica - 1 bočica sa praškom za otopinu za infuziju sadrži 400 jedinica velagluceraze alfa

Kesatuan Eropah - Croat - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Croatia - Croat - HALMED (Agencija za lijekove i medicinske proizvode)

sanyko d.o.o., zagreb - generator za perkutanu, laparoskopsku i intraoperativnu koagulaciju mekog tkiva, uključujući djelomičnu ili potpunu ablaciju ner